Dr. John R. Androsavich is General Manager of Datapoints at Ginkgo Bioworks, where he leads a Bio-AI Infrastructure platform focused on generating high-quality, multimodal biological datasets for machine learning in drug discovery. With over 15 years in genetic medicines, he has contributed to six clinical candidates and driven programs from target discovery through IND-enabling studies. He originated the target strategy and hit identification for Farabursen (anti-miR-17), a first-in-class therapeutic for ADPKD now entering Phase 3. Before Ginkgo, he served as Global Head of Emerging Science for RNA Medicine at Pfizer and held R&D leadership roles at Translate Bio and Regulus Therapeutics across mRNA and oligonucleotide platforms. His current work sits at the intersection of synthetic biology and AI—using programmable mammalian cell systems to generate functional genomic, transcriptomic, and phenotypic data that reveal how cells respond to chemical and genetic perturbation at scale. He holds a Ph.D. in Chemical Biology from the University of Michigan.